CHASE AWAY the CLOUDS - Providing temporary housing for cancer patients


Chase Away the Clouds is a nonprofit organization and as such does not take a stance on political issues.  The following is for your information and in no way reflects the views of Chase Away the Clouds positive or negative position on the country's health care law.

                              3/19/2014 Idaho Press Tribune - Politics
                                                                                  By:  Ricardo Alonso-Zaldivar

WASHINGTON (AP) --- Some of the nation's best cancer hospitals have been left out by insurers selling coverage under President Barack Obama's health care law.

For example, Seattle Cancer Care Alliance was excluded by five of eight insurers in the state's insurance exchange, or marketplace.  MD Anderson is in less than half the exchange plans in the Houston metro area.  Siteman Cancer Center in St. Louis is in some plans offered by one of two insurers on the Missouri exchange.

Only four of 19 nationally recognized cancer centers that responded to an Associate Press survey said patients have access through all the insurers in their states' exchanges.

Before the new health care law, a cancer diagnosis could make you uninsurable.  Now, you can get coverage, but the obstacle may be more subtle.

                                        4/6/2014 Idaho Statesman
                                                               By:  Mehmet OZ & Mike Roizen

Cancup 52 percent in Mexico, 55 percent in the U.S., and 66 percent in Canada.

                          see more at

                                                                    By:  Audrey Dutton

Stores and a popular restaurant have been developed in Nampa.

Nampa is growing, and so are its shopping possibilities.  A few big-box stores, a restaurant and a little-box store owned by big-box company have opened.  A lot of development is taking place on 12th Avenue.  Because of the new Saint Alphonsus Medical Center on Garrity Boulevard, there is tremendous growth in medical office buildings.  A new food market is also being discussed.

Nampa is the right place to build a cancer house! 

Report:  Cancer, heart disease 
leading causes of death in Idaho

                    Idaho Statesman
May 30, 2015

                                                                                                               By:  Kimberlee Kruesi
     Idaho saw the highest number of deaths in 2013 throughout the state since record-keeping began, with cancer barely squeezing out heart disease as the No. 1 cause, according to the state Department of Health and Welfare.
     The recently released report, Idaho Vital Statistics 2013, found more than 12,400 people died in Idaho in 2013.  The year prior, it was just shy of 12,000.                                                                 

More cancer success with drugs that enlist one's immune system

Idaho Press - Saturday May 30, 2015

                                                                                                                  By:  Lindsey Tanner

Doctors may be able to predict who will react well

CHICAGO--For the first time, a major study shows that a drug targeting the body's immune system may improve survival for the most common form of lung cancer.

These newer kinds of drugs have transformed treatment of melanoma, the deadliest kind of skin cancer.  Studies presented at a conference Friday suggest these "immune therapies" can play a broader tole in more common cancers, including lung, liver, colon, and head and neck.

Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Chicago meeting.  Immune therapy drugs are aimed at helping the body's immune system recognize and attack cancer.

The lung cancer study tested Bristol-Myers Squibb's Opdivo, which blocks a protein that prevents the immune system from attacking cancer cells.  It worked better than chemotherapy for patients with a form of non-small cell lung cancer that is diagnosed in more than 120,000 people nationwide each year.

Opdivo, also called nivolumab, was approved in March of lung cancer and late last year for melanoma.

These drugs are among the most promising drugs that have come along in many years, said Richard Schilsky, chief medical officer for the American Society of Clinical Oncology the meeting's organizer.